de Witte T, Novakova I, Branolte J, Muytjens H, de Pauw B
Department of Internal Medicine, University Hospital, Nijmegen, The Netherlands.
Pharm Weekbl Sci. 1987 Dec 11;9 Suppl:S48-52. doi: 10.1007/BF02075260.
The efficacy of oral ciprofloxacin to prevent bacterial infections during the first three months after allogeneic bone marrow transplantation (BMT) was assessed prospectively. Twenty-three recipients of lymphocyte depleted marrow grafts received ciprofloxacin orally, 500 mg twice daily for 90 days after BMT. Nine patients had no infections during ciprofloxacin prophylaxis; in the remaining 14 patients 19 febrile episodes occurred. No infections could be attributed to Gram-negative rods nor to fungal micro-organisms on the basis of the micro-organisms isolated. One infection, a pneumonia due to Bacteroides melaninogenicus, proved to be fatal. Allergic skin reactions were observed in three patients, but neither hematological nor nephrological side-effects could be substantiated in patients who were treated concomitantly with cyclosporine. Prolonged administration of ciprofloxacin turned out to be safe and effective in preventing serious aerobic bacterial infections during the first three months after BMT.
前瞻性评估了口服环丙沙星在异基因骨髓移植（BMT）后前三个月预防细菌感染的疗效。23例接受淋巴细胞清除骨髓移植的受者在BMT后口服环丙沙星，每日两次，每次500mg，共90天。9例患者在环丙沙星预防期间未发生感染；其余14例患者发生了19次发热发作。根据分离出的微生物，没有感染可归因于革兰氏阴性杆菌或真菌微生物。1例由产黑素拟杆菌引起的肺炎感染被证明是致命的。3例患者出现了过敏性皮肤反应，但在同时接受环孢素治疗的患者中，未证实有血液学或肾脏方面的副作用。结果表明，长期服用环丙沙星在预防BMT后前三个月严重需氧菌感染方面是安全有效的。
